Diabetic Neuropathy Treatment Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
Diabetic neuropathy is a common complication of diabetes that affects the nerves, causing symptoms such as numbness, tingling, pain, and weakness, typically starting in the feet and hands and gradually spreading throughout the body. The treatment of diabetic neuropathy primarily focuses on managing symptoms, slowing progression, and preventing complications. Several approaches are used in the treatment of diabetic neuropathy, including medication management to control pain and discomfort, blood sugar control to prevent further nerve damage, physical therapy to improve strength and mobility, and lifestyle changes such as a healthy diet and regular exercise.
CHAPTER 1. Industry Overview of Diabetic Neuropathy Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Diabetic Neuropathy Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Diabetic Neuropathy Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Diabetic Neuropathy Treatment Market By Disorder Type
1.2.3. Diabetic Neuropathy Treatment Market By Drug Class
1.2.4. Diabetic Neuropathy Treatment Market By Distribution Channel
1.2.5. Diabetic Neuropathy Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Diabetic Neuropathy Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Diabetic Neuropathy Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Diabetic Neuropathy Treatment Market By Disorder Type
5.1. Introduction
5.2. Diabetic Neuropathy Treatment Revenue By Disorder Type
5.2.1. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast, By Disorder Type, 2020-2032
5.2.2. Peripheral Neuropathy
5.2.2.1. Peripheral Neuropathy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Proximal Neuropathy
5.2.3.1. Proximal Neuropathy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Autonomic Neuropathy
5.2.4.1. Autonomic Neuropathy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Focal Neuropathy
5.2.5.1. Focal Neuropathy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Diabetic Neuropathy Treatment Market By Drug Class
6.1. Introduction
6.2. Diabetic Neuropathy Treatment Revenue By Drug Class
6.2.1. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032
6.2.2. Capsaicin
6.2.2.1. Capsaicin Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Opioid
6.2.3.1. Opioid Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3.2. Morphine
6.2.3.2.1. Morphine Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3.3. Others
6.2.3.3.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
6.2.4.1. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4.2. Ibuprofen
6.2.4.2.1. Ibuprofen Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4.3. Naproxen
6.2.4.3.1. Naproxen Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4.4. Others
6.2.4.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Antidepressants
6.2.5.1. Antidepressants Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5.2. Tricyclic Antidepressants (TCAs)
6.2.5.2.1. Tricyclic Antidepressants (TCAs) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5.3. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
6.2.5.3.1. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5.4. Selective Serotonin Reuptake Inhibitors (SSRIs)
6.2.5.4.1. Selective Serotonin Reuptake Inhibitors (SSRIs) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5.5. Anticonvulsant Drugs
6.2.5.5.1. Anticonvulsant Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.6. Other
6.2.6.1. Other Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Diabetic Neuropathy Treatment Market By Distribution Channel
7.1. Introduction
7.2. Diabetic Neuropathy Treatment Revenue By Distribution Channel
7.2.1. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
7.2.2. Hospitals Pharmacies
7.2.2.1. Hospitals Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Retail Pharmacies
7.2.3.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Others
7.2.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Diabetic Neuropathy Treatment Market By Country
8.1. North America Diabetic Neuropathy Treatment Market Overview
8.2. U.S.
8.2.1. U.S. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
8.2.2. U.S. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.2.3. U.S. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.3. Canada
8.3.1. Canada Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
8.3.2. Canada Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.3.3. Canada Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Diabetic Neuropathy Treatment Market By Country
9.1. Europe Diabetic Neuropathy Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
9.2.2. U.K. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.2.3. U.K. Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Germany
9.3.1. Germany Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
9.3.2. Germany Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.3.3. Germany Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. France
9.4.1. France Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
9.4.2. France Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.4.3. France Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.5. Spain
9.5.1. Spain Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
9.5.2. Spain Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.5.3. Spain Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
9.6.2. Rest of Europe Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.6.3. Rest of Europe Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Diabetic Neuropathy Treatment Market By Country
10.1. Asia Pacific Diabetic Neuropathy Treatment Market Overview
10.2. China
10.2.1. China Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
10.2.2. China Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.2.3. China Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Japan
10.3.1. Japan Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
10.3.2. Japan Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.3.3. Japan Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. India
10.4.1. India Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
10.4.2. India Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.4.3. India Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Australia
10.5.1. Australia Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
10.5.2. Australia Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.5.3. Australia Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.6. South Korea
10.6.1. South Korea Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
10.6.2. South Korea Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.6.3. South Korea Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
10.7.2. Rest of Asia-Pacific Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.7.3. Rest of Asia-Pacific Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Diabetic Neuropathy Treatment Market By Country
11.1. Latin America Diabetic Neuropathy Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
11.2.2. Brazil Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.2.3. Brazil Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. Mexico
11.3.1. Mexico Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
11.3.2. Mexico Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.3.3. Mexico Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
11.4.2. Rest of Latin America Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.4.3. Rest of Latin America Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Diabetic Neuropathy Treatment Market By Country
12.1. Middle East & Africa Diabetic Neuropathy Treatment Market Overview
12.2. GCC
12.2.1. GCC Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
12.2.2. GCC Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.2.3. GCC Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.3. South Africa
12.3.1. South Africa Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
12.3.2. South Africa Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.3.3. South Africa Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Disorder Type, 2020-2032
12.4.2. Rest of Middle East & Africa Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.4.3. Rest of Middle East & Africa Diabetic Neuropathy Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Diabetic Neuropathy Treatment Market
13.1. Diabetic Neuropathy Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Diabetic Neuropathy Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Abbott
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2022
14.1.3.2. Abbott 2022 Diabetic Neuropathy Treatment Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Pfizer Inc.
14.3. Eli Lilly and Company
14.4. Janssen Pharmaceuticals, Inc
14.5. Astellas Pharma Inc
14.6. Lupin Pharmaceuticals
14.7. Glenmark Pharmaceuticals Ltd
14.8. Novartis
14.9. Boehringer Ingelheim GmbH
Frequently Asked Questions
How big is the diabetic neuropathy treatment market?
The diabetic neuropathy treatment market size was USD 4.1Billionin 2022.
What is the CAGR of the global diabetic neuropathy treatment market from 2023 to 2032?
The CAGR of diabetic neuropathy treatment is 7.6% during the analysis period of 2023 to 2032.
Which are the key players in the diabetic neuropathy treatment market?
The key players operating in the global market are including Abbott, Pfizer Inc, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Astellas Pharma Inc, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Novartis, and Boehringer Ingelheim GmbH.
Which region dominated the global diabetic neuropathy treatment market share?
North America held the dominating position in diabetic neuropathy treatment industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of diabetic neuropathy treatment during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global diabetic neuropathy treatment industry?
The current trends and dynamics in the diabetic neuropathy treatment industry include increasing prevalence of diabetes worldwide, technological advancements in medical treatments and pharmaceuticals, and growing awareness about the importance of early intervention and management.
Which drug class held the maximum share in 2022?
The non-steroidal anti-inflammatory drugs (NSAIDs) class held the maximum share of the diabetic neuropathy treatment industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
